Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Pulmonology

Should COPD Patients Get Low-Dose CT Lung Cancer Screening?

At a Glance

Having COPD alone does not qualify someone for lung cancer screening. In the United States, yearly low-dose CT is generally recommended for adults ages 50–80 with at least 20 pack-years who smoke now or quit within 15 years and are healthy enough for curative treatment if cancer is found.

Having chronic obstructive pulmonary disease (COPD) does increase your risk for lung cancer, but a COPD diagnosis alone does not automatically mean you should be screened [1][2]. Routine lung cancer screening is based on your age and smoking history, not just whether you have a lung condition [1]. If you meet specific criteria, current guidelines recommend a yearly low-dose computed tomography (LDCT) scan [1]. An LDCT is a quick, painless X-ray that takes detailed pictures of your lungs using less radiation than a standard CT scan [1].

Who Is Eligible for Routine Screening?

In the United States, the U.S. Preventive Services Task Force (USPSTF) recommends yearly LDCT screening for people who meet all of the following criteria [1]:

  • Age: You are between 50 and 80 years old [1].
  • Smoking history: You have at least a “20 pack-year” smoking history [1]. A pack-year measures how much a person has smoked over time, calculated by multiplying the number of packs smoked per day by the number of years smoked (for example, 1 pack a day for 20 years, or 2 packs a day for 10 years) [3].
  • Current status: You currently smoke or have quit within the past 15 years [1]. Quitting does not immediately disqualify you; you remain eligible until 15 full years have passed [1].

Note: Medical guidelines and insurance coverage can sometimes differ. Always check with your insurance provider about your specific coverage.

Screening is typically stopped once you have been smoke-free for 15 years, turn 81, or develop a health condition that severely limits your life expectancy or ability to undergo curative treatment [1]. Having severe COPD does not automatically rule you out from screening. However, if cancer is found, you must be healthy enough—and willing—to undergo treatments intended to cure the cancer, which could include surgery or non-surgical options like focused radiation therapy [4]. Your doctor will help you decide if screening makes sense based on your lung function and overall health [4].

Screening vs. Investigating Symptoms

It is important to understand the difference between routine screening and diagnostic testing.

  • Routine Screening: This is for people who do not have any new or worsening symptoms of lung cancer [1]. Because people with COPD often have daily shortness of breath, screening is for when your symptoms are stable and at their normal baseline.
  • Diagnostic Testing: If you develop new, changing, or unexplained symptoms, you need a prompt medical evaluation—even if you do not meet the screening criteria [5][6].

Do not wait for a scheduled screening if you experience any of these warning signs [6]:

  • Hemoptysis (coughing up blood) [7]
  • Unexplained or new weight loss [6]
  • A new, persistent, or changing cough [6]
  • Persistent chest pain [6]
  • Recurrent lung infections or a severe, unexplained worsening of your shortness of breath [6]

If you have these symptoms, your doctor will choose the appropriate workup, which might start with a physical exam and a chest X-ray, or proceed to a diagnostic CT scan [5][6]. Seek emergency care if you have severe or rapidly worsening trouble breathing, severe chest pain, or are coughing up large amounts of blood [8].

Weighing the Risks and Benefits

Deciding to get screened involves shared decision-making with your doctor, weighing the potential benefits and risks based on your specific health [9].

The Benefits: For people at high risk, annual LDCT scans can find lung cancer at an early, more treatable stage, which reduces the risk of dying from the disease [10][11]. However, screening does not prevent cancer and does not catch every tumor.

The Risks:

  • False positives and extra testing: The scan may show a “nodule” or spot on your lung [10]. Most of these spots are benign (not cancer) and are just scars from past infections [10]. Usually, the next step is simply a repeat scan in a few months [12]. Rarely, a spot requires an invasive biopsy, which carries risks like a collapsed lung—a complication that can be more dangerous for someone with COPD [13][4].
  • Overdiagnosis: Screening may find a slow-growing cancer that would never have caused you harm during your lifetime, leading to unnecessary worry and treatment [14].
  • Radiation exposure: While an LDCT scan uses a small amount of radiation, getting one every year adds to your lifetime exposure [15].

If you currently smoke, the most effective way to lower your risk of lung cancer and slow your COPD is to stop smoking. Talk to your doctor about smoking-cessation support, such as counseling, nicotine-replacement therapies, or prescription medicines, or call a local quitline [1].

Common questions in this guide

Does having COPD by itself mean I should get annual lung cancer screening?
No. COPD can increase lung cancer risk, but in the United States annual low-dose CT screening is generally recommended for adults ages 50 to 80 who have at least 20 pack-years of smoking and currently smoke or quit within the past 15 years. You also need to be healthy enough and willing to receive treatment intended to cure lung cancer if it is found.
What smoking history qualifies someone for a low-dose CT?
The usual U.S. threshold is at least 20 pack-years, meaning the number of packs smoked per day multiplied by the years smoked. For example, one pack a day for 20 years or two packs a day for 10 years equals 20 pack-years. You can still qualify after quitting if you stopped within the past 15 years.
Can I wait for routine screening if I develop a new cough or breathlessness?
No. New, changing, or unexplained symptoms such as coughing up blood, unexplained weight loss, persistent chest pain, recurrent infections, or a major worsening of breathlessness need prompt medical evaluation even if you do not meet screening criteria. Severe breathing trouble, severe chest pain, or coughing up large amounts of blood requires emergency care.
Is low-dose CT appropriate for someone with severe COPD?
Severe COPD does not automatically exclude you from screening. Your clinician should consider your lung function, overall health, and whether you could safely and willingly undergo potentially curative surgery or focused radiation if cancer is found. Invasive follow-up tests such as a biopsy may carry a higher risk of a collapsed lung in people with COPD.
What happens if a low-dose CT finds a lung nodule?
Most nodules or spots found during screening are not cancer and may be scars from previous infections. The usual next step is often a repeat CT after a few months, although some findings require additional testing or a biopsy. A biopsy can rarely cause a collapsed lung.
Does annual low-dose CT prevent lung cancer?
No. Screening looks for cancer earlier, when it may be more treatable, and can lower the risk of dying from lung cancer in people at high risk, but it does not prevent every cancer or find every tumor. If you smoke, quitting is the most effective way to reduce lung cancer risk and slow COPD, and counseling, nicotine replacement, or prescription medicines can help.
Will my insurance cover low-dose CT screening if I have COPD?
Coverage rules can differ by insurer and may not exactly match medical screening guidelines. Ask your insurance provider whether annual low-dose CT is covered for your age and smoking history and whether a referral or prior authorization is required.

Get notified when new evidence is published on chronic obstructive pulmonary disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.

    , Krist AH, Davidson KW, et al.

    JAMA 2021; (325(10)):962-970 doi:10.1001/jama.2021.1117.

    PMID: 33687470
  2. 2

    Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry.

    Tisi S, Dickson JL, Horst C, et al.

    The European respiratory journal 2022; (60(6)) doi:10.1183/13993003.00795-2022.

    PMID: 35896207
  3. 3

    How the Expansion of the U.S. Preventive Services Task Force Lung Cancer Screening Eligibility May Improve Health Equity Among Diverse Sexual and Gender Minority Populations.

    Tan ASL, Potter J

    LGBT health 2021; (8(8)):503-506 doi:10.1089/lgbt.2021.0188.

    PMID: 34619037
  4. 4

    Lung Cancer Screening in Patients with COPD-A Case Report.

    Amirahmadi R, Kumar AJ, Cowan M, Deepak J

    Medicina (Kaunas, Lithuania) 2019; (55(7)) doi:10.3390/medicina55070364.

    PMID: 31336732
  5. 5

    Changes in diagnostic evaluation of patients with lung cancer symptoms.

    Sætre LMS, Balasubramaniam K, Wehberg S, et al.

    NPJ primary care respiratory medicine 2025; (35(1)):59 doi:10.1038/s41533-025-00464-4.

    PMID: 41271802
  6. 6

    Recognising Lung Cancer in Primary Care.

    Bradley SH, Kennedy MPT, Neal RD

    Advances in therapy 2019; (36(1)):19-30 doi:10.1007/s12325-018-0843-5.

    PMID: 30499068
  7. 7

    The Efficacy of Bronchoscopy versus Computerised Tomography in Initial Identification of Patients with Hemoptysis.

    He D, Huang D, Huang K, Liang Z

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2021; (31(12)):1459-1467 doi:10.29271/jcpsp.2021.12.1459.

    PMID: 34794288
  8. 8

    A systematic approach to the management of massive hemoptysis.

    Radchenko C, Alraiyes AH, Shojaee S

    Journal of thoracic disease 2017; (9(Suppl 10)):S1069-S1086 doi:10.21037/jtd.2017.06.41.

    PMID: 29214066
  9. 9

    Shared decision-making conversations and smoking cessation interventions: critical components of low-dose CT lung cancer screening programs.

    Lowenstein LM, Deyter GMR, Nishi S, et al.

    Translational lung cancer research 2018; (7(3)):254-271 doi:10.21037/tlcr.2018.05.10.

    PMID: 30050764
  10. 10

    Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Jonas DE, Reuland DS, Reddy SM, et al.

    JAMA 2021; (325(10)):971-987 doi:10.1001/jama.2021.0377.

    PMID: 33687468
  11. 11

    Lung Cancer Screening with Low-Dose CT: a Meta-Analysis.

    Hoffman RM, Atallah RP, Struble RD, Badgett RG

    Journal of general internal medicine 2020; (35(10)):3015-3025 doi:10.1007/s11606-020-05951-7.

    PMID: 32583338
  12. 12

    Incidental findings during lung low-dose computed tomography cancer screening in Australia and Canada, 2016-21: a prospective observational study.

    Bonney A, Pascoe DM, McCusker MW, et al.

    The Medical journal of Australia 2025; (222(8)):403-411 doi:10.5694/mja2.52649.

    PMID: 40320382
  13. 13

    Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.

    Pinsky PF, Gierada DS, Black W, et al.

    Annals of internal medicine 2015; (162(7)):485-91 doi:10.7326/M14-2086.

    PMID: 25664444
  14. 14

    The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials.

    Li M, Zhang L, Charvat H, et al.

    International journal of cancer 2022; (151(9)):1491-1501 doi:10.1002/ijc.34167.

    PMID: 35809038
  15. 15

    Radiation Exposure to Low-Dose Computed Tomography for Lung Cancer Screening: Should We Be Concerned?

    Pozzessere C, von Garnier C, Beigelman-Aubry C

    Tomography (Ann Arbor, Mich.) 2023; (9(1)):166-177 doi:10.3390/tomography9010015.

    PMID: 36828367

This page is for informational purposes only and does not constitute medical advice. A healthcare professional should assess your COPD, smoking history, symptoms, overall health, and ability to undergo treatment before you decide about low-dose CT screening.